Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 13, 2026, GlaxoSmithKline Pharmaceuticals Limited shareholders approved the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. The approvals were granted via postal ballot with a 99.71% approval rate. A total of 143,066,813 votes were in favor of Ms. Natland's appointment and 143,025,237 votes were in favor of Mr. Akshikar's re-appointment, out of 169,406,034 outstanding shares.
GlaxoSmithKline Pharmaceuticals Limited received a tax refund of ₹4,99,11,100 on August 18, 2026, following an intimation under section 143(1) of the Income Tax Act for the Assessment Year 2025-2026. The company reported no violations or contraventions in connection with this assessment, and the amount will be recorded in the Tax Paid Assets account.
As of September 18, 2026, the daily trend for GlaxoSmithKline Pharmaceuticals shows a bearish Supertrend at 3069.28, with the closing price at ₹2838.8. The weekly trend, however, indicates a bullish Supertrend at 2477.97. Key support levels are identified at ₹2818.9 (pivot) and ₹2775.5, while resistance levels are noted at ₹2843.3 and ₹2886.7.
On September 1, 2026, GlaxoSmithKline Pharmaceuticals Limited issued a corrigendum to its August 3, 2026 postal ballot notice. The correction clarified a typographical error in the basic salary figure for Mr. Akshikar, stating the correct monthly basic salary is ₹24,00,000, amending the previously published incorrect figure of ₹24,00,0000.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹938.44 crore | ₹995.30 crore | PEAK₹1,041.26 crore | ₹979.94 crore | ₹805.17 crore |
| Profit Before Exceptional Items And Tax | ₹322.45 crore | ₹373.10 crore | PEAK₹381.95 crore | ₹351.36 crore | ₹278.98 crore |
| Profit Before Tax | ₹322.45 crore | ₹373.10 crore | PEAK₹399.93 crore | ₹354 crore | ₹278.98 crore |
| Profit Loss For Period | ₹237.18 crore | ₹277.86 crore | PEAK₹295.62 crore | ₹257.49 crore | ₹205.01 crore |
| Other Expenses | PEAK₹155.96 crore | ₹135.62 crore | ₹154.22 crore | ₹150.63 crore | ₹113.69 crore |
| Basic Earnings Loss Per Share From Continuing And Discontinued Operations | ₹14 per share | ₹16.40 per share | PEAK₹16.54 per share | ₹15.07 per share | ₹12.10 per share |
Revenue from operations reached ₹938.44 crore in the quarter ended 30 June 2026. This was 16.55% higher than the ₹805.17 crore recorded in Q1 of the previous fiscal year. On a sequential basis, revenue fell 5.71% from ₹995.30 crore in Q4 FY2025-26. In the prior fiscal year, Q1 was the lowest-revenue quarter, with higher revenue in each of the following three quarters. The current quarter’s decline from Q4 is consistent with that pattern.
Basic and diluted earnings per share were both ₹14.00, up from ₹12.10 in the same quarter last year. The equality of basic and diluted EPS indicates no dilutive effect from potential shares. No exceptional items were recorded in the current quarter or in Q1 of the prior year, so the reported profit reflects ongoing operations.
GlaxoSmithkline Pharmaceuticals Limited delivered year-on-year growth in revenue and profit for Q1 FY2026-27. The quarter saw a sequential decline in both top and bottom lines, accompanied by a rise in other expenses that outpaced revenue growth. A reduction in finished goods inventory partially offset costs. The absence of exceptional items provides a clear view of operating performance.
Exchange disclosures and regulatory announcements for Glaxosmithkline Pharmaceuticals.
On September 13, 2026, GlaxoSmithKline Pharmaceuticals Limited shareholders approved two ordinary resolutions via postal ballot with a 99.71% approval rate: the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. The voting period ran from August 14 to September 13, 2026, utilizing remote e-voting through KFintech, resulting in 143,066,813 votes in favor for the director appointment and 143,025,237 votes in favor for the managing director re-appointment out of 169,406,034 outstanding shares.
GlaxoSmithKline Pharmaceuticals Limited issued a corrigendum on September 1, 2026, correcting a typographical error in the basic salary figure of Mr. Akshikar in the explanatory statement of its August 3, 2026 postal ballot notice; the correct basic salary is Rs. 24,00,000 per month, not Rs. 24,00,0000 per month. Separately, Sical Logistics Limited announced its 71st Annual General Meeting will be held on September 30, 2026, at 1:30 p.m. via video conferencing, with the annual report for the financial year ended March 31, 2026, sent electronically to members.
On September 1, 2026, GlaxoSmithKline Pharmaceuticals Limited issued a corrigendum to its August 3, 2026 postal ballot notice to correct a typographical error in the basic salary figure for Mr. Akshikar. The correction clarifies that the monthly basic salary is Rs. 24,00,000/- per month, amending the previously stated incorrect figure of Rs. 24,00,0000/-. This corrigendum forms an integral part of the original notice and explanatory statement circulated on August 13, 2026.
GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026 |SUBJECT: General Updates
GlaxoSmithKline Pharmaceuticals Limited received a tax refund of Rs 4,99,11,100 following an intimation under section 143(1) of the Income Tax Act for the Assessment Year 2025-2026. The refund was credited to the company's bank account on August 18, 2026, and the intimation was formally received on August 19, 2026. No violations or contraventions were reported in connection with this assessment, and the amount will be recorded in the Tax Paid Assets account.
GlaxoSmithKline Pharmaceuticals Limited announced the dispatch of a Postal Ballot Notice to members as of the cut-off date of August 7, 2026, for voting on two resolutions: the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. Remote e-voting is open from August 14, 2026, to September 13, 2026, with results to be declared on or before September 15, 2026.
GlaxoSmithKline Pharmaceuticals Limited is seeking shareholder approval via postal ballot for the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. Mr. Akshikar's re-appointment is for a two-year period from 1st December 2026 to 30th November 2028, with a basic salary not exceeding Rs 24,00,000 per month and additional performance-based remuneration. The e-voting period runs from 14th August 2026 to 13th September 2026, with results to be announced on or before 15th September 2026.
Glaxosmithkline Pharmaceuticals Limited announced on August 13, 2026, that it will hold a postal ballot meeting on August 14, 2026, to seek shareholder approval for two resolutions. The first resolution proposes the appointment of Ms. Karine J F Natland (DIN: 11870917) as a Non-Executive Non-Independent Director with a tenure commencing and ending on August 4, 2026. The second resolution seeks the re-appointment of Mr. Bhushan Akshikar (DIN: 09112346) as Managing Director for a term from December 1, 2026, to November 30, 2028.
Recent market and company developments associated with Glaxosmithkline Pharmaceuticals.
Experts suggest capitalising on bullish momentum by targeting six stocks poised for growth over the next 1-2 weeks. With a focus on disciplined risk management, this article reveals key levels and potential upside for smart investors seeking short-term opportunities.
The company's net profit stood at ₹237.1 crore for the first quarter of FY27, compared with ₹205 crore a year earlier. Revenue from operations increased 16.6% to ₹938 crore from ₹805 crore in the corresponding quarter last year.
Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%.
Comprehensive Section Breakdown for Glaxosmithkline Pharmaceuticals
Strategic Vision: Develops and delivers medicines and vaccines for global health.
• Research-based approach to medicine and vaccine development.
• Focus on specific therapeutic areas for specialized expertise.
GlaxoSmithkline Pharmaceuticals Limited reported revenue of ₹938.44 crore for the first quarter of FY2026-27, a 16.55% increase over the same quarter last year. Net profit rose 15.7% to ₹237.18 crore. Compared to the immediately preceding quarter, revenue and profit declined, while other expenses grew faster than revenue. A reduction in finished goods inventory helped contain total costs for the quarter.
Profit Before Tax (PBT) stood at ₹322.45 crore, a year-on-year increase of 15.58% from ₹278.98 crore. Sequentially, PBT declined 13.58% from ₹373.10 crore in Q4 FY2025-26. The PBT margin was 34.4% in the current quarter, compared with 37.5% in the previous quarter and 34.7% in Q1 of the prior year. The sequential margin compression reflects that costs did not fall in proportion to the revenue decline.
Net profit for the period was ₹237.18 crore, up 15.7% from ₹205.01 crore a year earlier. The effective tax rate was approximately 26.4% of PBT, compared with 26.5% in the year-ago quarter.
Among the reported expense items, Other Expenses rose sharply. At ₹155.96 crore, they were 37.18% higher than the ₹113.69 crore in Q1 FY2025-26 and 15.0% higher than the ₹135.62 crore in Q4 FY2025-26. This growth rate exceeded the 16.55% year-on-year revenue increase.
Employee Benefit Expense was ₹159.04 crore and Cost of Materials Consumed was ₹72.95 crore. Finance Costs were ₹0.97 crore, up from ₹0.42 crore a year earlier. Depreciation was ₹15.84 crore.
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade showed a negative ₹123.63 crore, indicating a reduction in inventory levels. This acted as a credit, lowering total expenses for the quarter.
GSK India delivered strong Q1 FY27 growth with revenue up 15% YoY to INR 924 crores and PAT rising 24% to INR 253 crores. Management stated this performance reflects continued progress in portfolio transformation, supported by execution excellence and favorable base effects. The innovation portfolio, comprising Oncology and New Respiratory therapies, now accounts for 7% of total sales, driving one-fourth of headline growth compared to 4% in the prior year.
Future outlook remains positive as the company prepares for key pipeline launches such as Blenrep and Arexvy while strengthening supply chain resilience through diversified sourcing. Strategic focus areas include accelerating R&D, simplifying operations through AI and technology, and a long-term vision to double General Medicines' growth engine sales by 2030.
Category: Healthcare
The company discovers, develops, and delivers medicines and vaccines across four key therapeutic areas. It offers a range of pharmaceutical products in India.
Key Products & Services: Ambiform 1000mg Tablet • Antepar 750mg Syrup • Atcor 20mg Tablet • Avamys Nasal Spray • Betnovate 0.12% Lotion • Bactroban 2% Ointment • Banocide 50mg Tablet • Becadexamin Multivitamin & Multimineral Capsule • Becoride 250mcg Inhaler • Becoride Forte 250mcg Inhaler • Betnovate M Cream • Betnovate-GM Cream • Bidanzen Forte Tablet • Bidopal 500mg Tablet • Boostrix Vaccine • Bronko Plus 2mg/100mg Syrup • Bronkotab EX Tablet • Calpol 250mg Tablet • Calpol 500 + Tablet • Calpol Paediatric Drops Peppermint • Cefizox 500mg Injection • Cefspan 100mg Capsule • Dapsone 50mg Tablet • Dapsone Tablet • Detnovate GM Cream • Digoxin 0.25mg Tablet • Digoxin 50mcg/ml Elixir • Dilosyn Bm Expectorant • Dilosyn Expectorant • Drapolene Cream • Duofilm Solution • Efcorlin 2.5mg Pellets • Eltroxin 25mcg Tablet • Eskaycillin 500mg Capsule • Fetugard 5mg Tablet • Flutivate E Cream • Fortum 250mg Injection • Fraxiparine 6150IU Injection • Frusemene 40 mg/50 mg Tablet • Furacin Ointment • Glamoxin 125mg Tablet • H Supacef 1500mg Injection • Havrix 720 Junior Monodose Vaccine • Hycamtin 1mg Tablet • Ictacetam 250mg Tablet • Infanrix Hexa Vaccine • Kemadrin 2.5mg Tablet • Kemadrin 5mg Tablet • Lamictal 50mg Tablet DT
Core Thesis: The company leverages its R&D capabilities to discover, develop, and deliver medicines and vaccines.
• Research and Development: R&D efforts are concentrated in four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. • Product Delivery: The company focuses on delivering a range of pharmaceutical products and vaccines to the market.